Monash IVF Group Limited

ASX MVF.AX

Monash IVF Group Limited EBITDA Margin for the year ending June 30, 2024: 5.11%

Monash IVF Group Limited EBITDA Margin is 5.11% for the year ending June 30, 2024, a -77.50% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Monash IVF Group Limited EBITDA Margin for the year ending June 30, 2023 was 22.70%, a -4.47% change year over year.
Monash IVF Group Limited EBITDA Margin for the year ending June 30, 2022 was 23.76%, a -14.80% change year over year.
Monash IVF Group Limited EBITDA Margin for the year ending June 30, 2021 was 27.89%, a 23.49% change year over year.
Monash IVF Group Limited EBITDA Margin for the year ending June 30, 2020 was 22.59%, a -5.84% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

ASX: MVF.AX

Monash IVF Group Limited

CEO	Mr. Michael D. Knaap
IPO Date	June 26, 2014
Location	Australia
Headquarters	Pelaco Building 1
Employees	997
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Dental Care Medical Instruments Professional Services Telehealth Venture Capital

Description

Monash IVF Group Limited provides assisted reproductive and specialist women imaging services in Australia and Malaysia. The company offers diagnostic obstetric, gynecological ultrasound, and fertility treatment services. It also provides tertiary level prenatal diagnostic and IVF treatment services. The company was incorporated in 2014 and is based in Richmond, Australia.

Key trends

Past 5 years